TY - JOUR AU - Kalathil, S. G. AU - Thanavala, Y. PY - 2016 DA - 2016// TI - High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy JO - Cancer Immunol Immunother VL - 65 UR - https://doi.org/10.1007/s00262-016-1810-0 DO - 10.1007/s00262-016-1810-0 ID - Kalathil2016 ER - TY - STD TI - Tsirigotis P, Savani BN, Nagler A. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies. Ann Med. 2016:1–12. ID - ref2 ER - TY - JOUR AU - Ulmeanu, R. AU - Antohe, I. AU - Anisie, E. AU - Antoniu, S. PY - 2016 DA - 2016// TI - Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study JO - Expert Rev Anticancer Ther VL - 16 UR - https://doi.org/10.1586/14737140.2016.1127760 DO - 10.1586/14737140.2016.1127760 ID - Ulmeanu2016 ER - TY - JOUR AU - Borghaei, H. AU - Paz-Ares, L. AU - Horn, L. AU - Spigel, D. R. AU - Steins, M. AU - Ready, N. E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1507643 DO - 10.1056/NEJMoa1507643 ID - Borghaei2015 ER - TY - JOUR AU - Brahmer, J. AU - Reckamp, K. L. AU - Baas, P. AU - Crino, L. AU - Eberhardt, W. E. AU - Poddubskaya, E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504627 DO - 10.1056/NEJMoa1504627 ID - Brahmer2015 ER - TY - JOUR AU - Lim, S. H. AU - Sun, J. M. AU - Lee, S. H. AU - Ahn, J. S. AU - Park, K. AU - Ahn, M. J. PY - 2016 DA - 2016// TI - Pembrolizumab for the treatment of non-small cell lung cancer JO - Expert Opin Biol Ther VL - 16 UR - https://doi.org/10.1517/14712598.2016.1145652 DO - 10.1517/14712598.2016.1145652 ID - Lim2016 ER - TY - JOUR AU - Sansom, D. M. PY - 2000 DA - 2000// TI - CD28, CTLA-4 and their ligands: who does what and to whom? JO - Immunology VL - 101 UR - https://doi.org/10.1046/j.1365-2567.2000.00121.x DO - 10.1046/j.1365-2567.2000.00121.x ID - Sansom2000 ER - TY - JOUR AU - Hodi, F. S. AU - O'Day, S. J. AU - McDermott, D. F. AU - Weber, R. W. AU - Sosman, J. A. AU - Haanen, J. B. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Larkin, J. AU - Hodi, F. S. AU - Wolchok, J. D. PY - 2015 DA - 2015// TI - Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504030 DO - 10.1056/NEJMoa1504030 ID - Larkin2015 ER - TY - JOUR AU - Robert, C. AU - Thomas, L. AU - Bondarenko, I. AU - O'Day, S. AU - Weber, J. AU - Garbe, C. PY - 2011 DA - 2011// TI - Ipilimumab plus dacarbazine for previously untreated metastatic melanoma JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1104621 DO - 10.1056/NEJMoa1104621 ID - Robert2011 ER - TY - JOUR AU - Weber, J. S. AU - Kahler, K. C. AU - Hauschild, A. PY - 2012 DA - 2012// TI - Management of immune-related adverse events and kinetics of response with ipilimumab JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2012.41.6750 DO - 10.1200/JCO.2012.41.6750 ID - Weber2012 ER - TY - JOUR AU - Costa, R. AU - Carneiro, B. A. AU - Agulnik, M. AU - Rademaker, A. W. AU - Pai, S. G. AU - Villaflor, V. M. PY - 2017 DA - 2017// TI - Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials JO - Oncotarget VL - 8 ID - Costa2017 ER - TY - JOUR AU - Weber, J. S. AU - D'Angelo, S. P. AU - Minor, D. AU - Hodi, F. S. AU - Gutzmer, R. AU - Neyns, B. PY - 2015 DA - 2015// TI - Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70076-8 DO - 10.1016/S1470-2045(15)70076-8 ID - Weber2015 ER - TY - JOUR AU - Robert, C. AU - Schachter, J. AU - Long, G. V. AU - Arance, A. AU - Grob, J. J. AU - Mortier, L. PY - 2015 DA - 2015// TI - Pembrolizumab versus Ipilimumab in advanced melanoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1503093 DO - 10.1056/NEJMoa1503093 ID - Robert2015 ER - TY - JOUR AU - Weber, J. S. AU - Yang, J. C. AU - Atkins, M. B. AU - Disis, M. L. PY - 2015 DA - 2015// TI - Toxicities of immunotherapy for the practitioner JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.60.0379 DO - 10.1200/JCO.2014.60.0379 ID - Weber2015 ER - TY - JOUR AU - Postow, M. A. AU - Chesney, J. AU - Pavlick, A. C. AU - Robert, C. AU - Grossmann, K. AU - McDermott, D. PY - 2015 DA - 2015// TI - Nivolumab and ipilimumab versus ipilimumab in untreated melanoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1414428 DO - 10.1056/NEJMoa1414428 ID - Postow2015 ER - TY - JOUR AU - Rizvi, N. A. AU - Hellmann, M. D. AU - Brahmer, J. R. AU - Juergens, R. A. AU - Borghaei, H. AU - Gettinger, S. PY - 2016 DA - 2016// TI - Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.66.9861 DO - 10.1200/JCO.2016.66.9861 ID - Rizvi2016 ER - TY - JOUR AU - Kobold, S. AU - Duewell, P. AU - Schnurr, M. AU - Subklewe, M. AU - Rothenfusser, S. AU - Endres, S. PY - 2015 DA - 2015// TI - Immunotherapy in tumors JO - Dtsch Arztebl Int VL - 112 ID - Kobold2015 ER - TY - JOUR AU - Spain, L. AU - Diem, S. AU - Larkin, J. PY - 2016 DA - 2016// TI - Management of toxicities of immune checkpoint inhibitors JO - Cancer Treat Rev VL - 44 UR - https://doi.org/10.1016/j.ctrv.2016.02.001 DO - 10.1016/j.ctrv.2016.02.001 ID - Spain2016 ER - TY - STD TI - Horneber MA, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev. 2008;(2):CD003297. doi:10.1002/14651858.CD003297.pub2. ID - ref20 ER - TY - JOUR AU - Troger, W. AU - Galun, D. AU - Reif, M. AU - Schumann, A. AU - Stankovic, N. AU - Milicevic, M. PY - 2013 DA - 2013// TI - Viscum Album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2013.06.043 DO - 10.1016/j.ejca.2013.06.043 ID - Troger2013 ER - TY - JOUR AU - Ostermann, T. AU - Raak, C. AU - Bussing, A. PY - 2009 DA - 2009// TI - Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review JO - BMC Cancer VL - 9 UR - https://doi.org/10.1186/1471-2407-9-451 DO - 10.1186/1471-2407-9-451 ID - Ostermann2009 ER - TY - JOUR AU - Ostermann, T. AU - Bussing, A. PY - 2012 DA - 2012// TI - Retrolective studies on the survival of cancer patients treated with mistletoe extracts: a meta-analysis JO - Explore (NY) VL - 8 UR - https://doi.org/10.1016/j.explore.2012.06.005 DO - 10.1016/j.explore.2012.06.005 ID - Ostermann2012 ER - TY - JOUR AU - Bock, P. R. AU - Friedel, W. E. AU - Hanisch, J. AU - Karasmann, M. AU - Schneider, B. PY - 2004 DA - 2004// TI - Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum Album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland JO - Arzneimittelforschung VL - 54 ID - Bock2004 ER - TY - JOUR AU - Deng, G. E. AU - Rausch, S. M. AU - Jones, L. W. AU - Gulati, A. AU - Kumar, N. B. AU - Greenlee, H. PY - 2013 DA - 2013// TI - Complementary therapies and integrative medicine in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines JO - Chest VL - 143 UR - https://doi.org/10.1378/chest.12-2364 DO - 10.1378/chest.12-2364 ID - Deng2013 ER - TY - JOUR AU - Greenlee, H. AU - Balneaves, L. G. AU - Carlson, L. E. AU - Cohen, M. AU - Deng, G. AU - Hershman, D. PY - 2014 DA - 2014// TI - Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer JO - J Natl Cancer Inst Monogr VL - 2014 UR - https://doi.org/10.1093/jncimonographs/lgu041 DO - 10.1093/jncimonographs/lgu041 ID - Greenlee2014 ER - TY - STD TI - Horneber M, Bueschel G. Mistletoe therapy in oncology (Cochran review). 2008. ID - ref27 ER - TY - JOUR AU - Axtner, J. AU - Steele, M. AU - Kroz, M. AU - Spahn, G. AU - Matthes, H. AU - Schad, F. PY - 2016 DA - 2016// TI - Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer JO - BMC Cancer VL - 16 UR - https://doi.org/10.1186/s12885-016-2594-5 DO - 10.1186/s12885-016-2594-5 ID - Axtner2016 ER - TY - JOUR AU - Deng, G. E. AU - Frenkel, M. AU - Cohen, L. AU - Cassileth, B. R. AU - Abrams, D. I. AU - Capodice, J. L. PY - 2009 DA - 2009// TI - Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals JO - J Soc Integr Oncol VL - 7 ID - Deng2009 ER - TY - STD TI - Schad F, Axtner J, Kröz M, Matthes H, Steele M. Safety of Combined Treatment with Monoclonal Antibodies and Viscum album L preparations. Integr Cancer Ther. 2016. DOI:10.1177/1534735416681641. http://journals.sagepub.com/doi/pdf/10.1177/1534735416681641. Accessed 27 Nov 2017. UR - http://journals.sagepub.com/doi/pdf/10.1177/1534735416681641 ID - ref30 ER - TY - JOUR AU - Steele, M. L. AU - Axtner, J. AU - Happe, A. AU - Kroz, M. AU - Matthes, H. AU - Schad, F. PY - 2014 DA - 2014// TI - Safety of intravenous application of mistletoe (Viscum Album L.) preparations in oncology: an observational study JO - Evid Based Complement Alternat Med VL - 2014 ID - Steele2014 ER - TY - JOUR AU - Steele, M. L. AU - Axtner, J. AU - Happe, A. AU - Kroz, M. AU - Matthes, H. AU - Schad, F. PY - 2014 DA - 2014// TI - Adverse drug reactions and expected effects to therapy with subcutaneous mistletoe extracts (Viscum Album L.) in cancer patients JO - Evid Based Complement Alternat Med VL - 2014 ID - Steele2014 ER - TY - JOUR AU - Steele, M. L. AU - Axtner, J. AU - Happe, A. AU - Kroz, M. AU - Matthes, H. AU - Schad, F. PY - 2015 DA - 2015// TI - Use and safety of intratumoral application of European mistletoe (Viscum Album L) preparations in oncology JO - Integr Cancer Ther VL - 14 UR - https://doi.org/10.1177/1534735414563977 DO - 10.1177/1534735414563977 ID - Steele2015 ER - TY - JOUR AU - Bussing, A. AU - Raak, C. AU - Ostermann, T. PY - 2012 DA - 2012// TI - Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis JO - Evid Based Complement Alternat Med VL - 2012 ID - Bussing2012 ER - TY - JOUR AU - Lee, S. J. AU - Son, Y. O. AU - Kim, H. AU - Kim, J. Y. AU - Park, S. W. AU - Bae, J. H. PY - 2007 DA - 2007// TI - Suppressive effect of a standardized mistletoe extract on the expression of activatory NK receptors and function of human NK cells JO - J Clin Immunol VL - 27 UR - https://doi.org/10.1007/s10875-007-9098-7 DO - 10.1007/s10875-007-9098-7 ID - Lee2007 ER - TY - JOUR AU - Heinzerling, L. AU - von Baehr, V. AU - Liebenthal, C. AU - von Baehr, R. AU - Volk, H. D. PY - 2006 DA - 2006// TI - Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo JO - J Clin Immunol VL - 26 UR - https://doi.org/10.1007/s10875-006-9023-5 DO - 10.1007/s10875-006-9023-5 ID - Heinzerling2006 ER - TY - JOUR AU - Thies, A. AU - Nugel, D. AU - Pfuller, U. AU - Moll, I. AU - Schumacher, U. PY - 2005 DA - 2005// TI - Influence of mistletoe lectins and cytokines induced by them on cell proliferation of human melanoma cells in vitro JO - Toxicology VL - 207 UR - https://doi.org/10.1016/j.tox.2004.09.009 DO - 10.1016/j.tox.2004.09.009 ID - Thies2005 ER - TY - JOUR AU - Weissenstein, U. AU - Kunz, M. AU - Urech, K. AU - Regueiro, U. AU - Baumgartner, S. PY - 2016 DA - 2016// TI - Interaction of a standardized mistletoe (Viscum Album) preparation with antitumor effects of Trastuzumab in vitro JO - BMC Complement Altern Med VL - 16 UR - https://doi.org/10.1186/s12906-016-1246-2 DO - 10.1186/s12906-016-1246-2 ID - Weissenstein2016 ER - TY - JOUR AU - Bar-Sela, G. AU - Wollner, M. AU - Hammer, L. AU - Agbarya, A. AU - Dudnik, E. AU - Haim, N. PY - 2013 DA - 2013// TI - Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2012.11.007 DO - 10.1016/j.ejca.2012.11.007 ID - Bar-Sela2013 ER - TY - JOUR AU - Bussing, A. PY - 2006 DA - 2006// TI - Immune modulation using mistletoe (Viscum Album L.) extracts Iscador JO - Arzneimittelforschung VL - 56 ID - Bussing2006 ER - TY - STD TI - Deutsche Krebsgesellschaft. Annual Report 2016 of the Certified Oncology Centres http://www.onkozert.de/downloads/2016_jahresbericht-oz-en-A2%20%28160321%29.pdf. Assessed 27 November 2017. UR - http://www.onkozert.de/downloads/2016_jahresbericht-oz-en-A2%20%28160321%29.pdf ID - ref41 ER - TY - STD TI - OPDIVO, INN-nivolumab - Annex I, summary of product characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003985/WC500189765.pdf. Assessed 27 November 2017. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003985/WC500189765.pdf ID - ref42 ER - TY - STD TI - Yervoy: Annex I, Summary of Product Characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002213/WC500109299.pdf. Assessed 27 November 2017. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002213/WC500109299.pdf ID - ref43 ER - TY - STD TI - Keytruda, INN-pembrolizumab, annex I, summary of product characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003820/WC500190990.pdf. Assessed 27 November 2017. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003820/WC500190990.pdf ID - ref44 ER - TY - STD TI - Scherer R. Sample Size Calculation for Various t-Tests and Wilcoxon-Test. https://cran.r-project.org/web/packages/samplesize/samplesize.pdf. Accessed 27 Nov 2017. UR - https://cran.r-project.org/web/packages/samplesize/samplesize.pdf ID - ref45 ER - TY - JOUR AU - Schad, F. AU - Axtner, J. AU - Happe, A. AU - Breitkreuz, T. AU - Paxino, C. AU - Gutsch, J. PY - 2013 DA - 2013// TI - Network oncology (NO)--a clinical cancer register for health services research and the evaluation of integrative therapeutic interventions in anthroposophic medicine JO - Forsch Komplementmed VL - 20 UR - https://doi.org/10.1159/000356204 DO - 10.1159/000356204 ID - Schad2013 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. AU - Sargent, D. AU - Ford, R. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - STD TI - International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf. Accessed 27 November 2017. UR - http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf ID - ref48 ER - TY - STD TI - National Cancer Institute, Division of Cancer Treatment and Diagnosis, Common Terminology Criteria for Adverse Events (CTCAE) v.4.0 https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 27 November 2017. UR - https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm ID - ref49 ER - TY - STD TI - R: A language and environment for statistical computing. R Foundation for Statistical Computing https://www.R-project.org/. Accessed 27 November 2017. UR - https://www.r-project.org ID - ref50 ER - TY - JOUR AU - Naidoo, J. AU - Page, D. B. AU - Li, B. T. AU - Connell, L. C. AU - Schindler, K. AU - Lacouture, M. E. PY - 2015 DA - 2015// TI - Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies JO - Ann Oncol VL - 26 ID - Naidoo2015 ER - TY - JOUR AU - Kim, J. J. AU - Hwang, Y. H. AU - Kang, K. Y. AU - Kim, I. AU - Kim, J. B. AU - Park, J. H. PY - 2014 DA - 2014// TI - Enhanced dendritic cell maturation by the B-chain of Korean mistletoe lectin (KML-B), a novel TLR4 agonist JO - Int Immunopharmacol VL - 21 UR - https://doi.org/10.1016/j.intimp.2014.05.010 DO - 10.1016/j.intimp.2014.05.010 ID - Kim2014 ER - TY - JOUR AU - Hostanska, K. AU - Hajto, T. AU - Spagnoli, G. C. AU - Fischer, J. AU - Lentzen, H. AU - Herrmann, R. A. PY - 1995 DA - 1995// TI - Plant lectin derived from Viscum Album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells JO - Nat Immun VL - 14 ID - Hostanska1995 ER - TY - JOUR AU - Gardin, N. E. PY - 2009 DA - 2009// TI - Immunological response to mistletoe (Viscum Album L.) in cancer patients: a four-case series JO - Phytother Res VL - 23 UR - https://doi.org/10.1002/ptr.2643 DO - 10.1002/ptr.2643 ID - Gardin2009 ER - TY - JOUR AU - Hajto, T. AU - Hostanska, K. AU - Weber, K. AU - Zinke, H. AU - Fischer, J. AU - Mengs, U. PY - 1998 DA - 1998// TI - Effect of a recombinant lectin, Viscum Album agglutinin on the secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity of rat splenocytes in vitro and in vivo JO - Nat Immun VL - 16 UR - https://doi.org/10.1159/000069428 DO - 10.1159/000069428 ID - Hajto1998 ER - TY - JOUR AU - Bock, P. R. AU - Hanisch, J. AU - Matthes, H. AU - Zanker, K. S. PY - 2014 DA - 2014// TI - Targeting inflammation in cancer-related-fatigue: a rationale for mistletoe therapy as supportive care in colorectal cancer patients JO - Inflamm Allergy Drug Targets VL - 13 UR - https://doi.org/10.2174/1871528113666140428103332 DO - 10.2174/1871528113666140428103332 ID - Bock2014 ER - TY - JOUR AU - Eisenbraun, J. AU - Scheer, R. AU - Kröz, M. AU - Schad, F. AU - Huber, R. PY - 2011 DA - 2011// TI - Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract JO - Phytomedicine : international journal of phytotherapy and phytopharmacology VL - 18 UR - https://doi.org/10.1016/j.phymed.2010.06.013 DO - 10.1016/j.phymed.2010.06.013 ID - Eisenbraun2011 ER -